Bronchodilation with a potent and selective leukotriene D4 (LTD4) receptor antagonist (MK-571) in patients with asthma.

The sulfidopeptide leukotrienes LTC4, LTD4, and LTE4 can cause airway smooth muscle contraction and have been implicated in the pathophysiology of asthma. MK-571 is a selective, potent LTD4 receptor antagonist that could attenuate airway obstruction in asthma by inhibiting the actions of sulfidopeptides at the LTD4 receptor site. The objectives of this study were to investigate the potential for MK-571 to cause bronchodilation in asthma patients with existing airway obstruction and to evaluate its effect on the bronchodilation response to an inhaled beta 2-agonist (albuterol). Twelve male patients (ages 19 to 42 yr) with asthma (baseline FEV1 50 to 80% predicted) participated in this placebo-controlled, randomized, two-period, cross-over study. On separate treatment days, each patient received either MK-571 or placebo intravenously for 6 h; inhaled albuterol was administered at the fifth and sixth hour of MK-571/placebo treatment to achieve maximal bronchodilation on that study day. Spirometry (forced expiratory volume in 1 s, FEV1) was monitored at intervals throughout each study period. MK-571 caused clinically significant bronchodilation; the increase in FEV1 above baseline, 20 min after the start of the MK-571 infusion, was 22 +/- 3.9% compared with 1.3 +/- 2.3% for placebo (mean +/- SE, p < 0.01). This degree of bronchodilation was maintained throughout the MK-571 infusion. In addition, bronchodilation from inhaled albuterol appeared additive with MK-571. Finally, baseline airway obstruction correlated with the degree of bronchodilation achieved with MK-571 (r = -0.73; p = 0.007).(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  K. P. Hui,et al.  Lung function improvement in asthma with a cysteinylleukotriene receptor antagonist , 1991, The Lancet.

[2]  A. Ford-hutchinson,et al.  Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. , 1991, The American review of respiratory disease.

[3]  S. Wenzel,et al.  Elevated levels of leukotriene C4 in bronchoalveolar lavage fluid from atopic asthmatics after endobronchial allergen challenge. , 1990, The American review of respiratory disease.

[4]  R. Krell,et al.  In vitro metabolism of [3H]-peptide leukotrienes in human and ferret lung: a comparison with the guinea pig. , 1985, Biochemical and biophysical research communications.

[5]  S. Murota,et al.  Measurement of immunoreactive leukotriene C4 in blood of asthmatic children. , 1985, Biochemical and biophysical research communications.

[6]  K. Austen,et al.  Release of leukotrienes by human monocytes on stimulation of their phagocytic receptor for particulate activators. , 1984, Journal of immunology.

[7]  E. Corey,et al.  Generation and metabolism of 5-lipoxygenase pathway leukotrienes by human eosinophils: predominant production of leukotriene C4. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[8]  S. Peters,et al.  Generation of leukotrienes by purified human lung mast cells. , 1982, The Journal of clinical investigation.

[9]  S. Dahlén,et al.  Leukotrienes promote plasma leakage and leukocyte adhesion in postcapillary venules: in vivo effects with relevance to the acute inflammatory response. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Bengt Samuelsson,et al.  Leukotrienes are potent constrictors of human bronchi , 1980, Nature.

[11]  E. Corey,et al.  Comparative airway and vascular activities of leukotrienes C-1 and D in vivo and in vitro. , 1980, Proceedings of the National Academy of Sciences of the United States of America.